Posted on 1/7/19
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Bristol-Myers Squibb (NYSE:BMY) is acquiring Celgene (NASDAQ:CELG) for roughly $74 billion to create a biopharma goliath. The combined company will boast eight billion-dollar blockbuster drugs and . . .
Posted on 1/7/19
Should Celgene Investors Take Bristol's Money and Run?
In 2018, Bristol-Myers Squibb (NYSE:BMY) relied on just two products to drive growth, and the pharma giant's late-stage development pipeline looks like Old Mother Hubbard's cupboards. . . .
Posted on 1/7/19
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
2019 has started off with a bang in the biopharmaceutical industry. On Thursday, Bristol-Myers Squibb (NYSE:BMY) announced that it planned to acquire Celgene (NASDAQ:CELG) in a . . .
Posted on 1/4/19
Bristol-Myers: Analysis On Celgene Deal
Summary Bristol-Myers announced a $90-billion deal for Celgene, roughly equal to its own valuation. The deal is not really welcomed by investors, which shun mega-merger deals . . .
Posted on 1/4/19
Here’s What Celgene Shareholders Are Getting From Bristol-Myers Squibb
The opportunity to secure potential best-selling drugs before they win FDA approval convinced pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) to acquire biotechnology giant Celgene (NASDAQ:CELG) on Jan. . . .
Posted on 1/3/19
Knopp Biosciences Enters Research Collaboration with Baylor College of Medicine
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet . . .
Posted on 1/3/19
Knopp Biosciences Enters Research Collaboration with Baylor College of Medicine
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet . . .
Posted on 1/3/19
Conduent Completes Acquisition of Health Solutions Plus
Conduent Incorporated (NYSE: CNDT) today announced it has completed its acquisition of Health Solutions Plus (HSP), a software provider of healthcare payer administration solutions.
Posted on 1/3/19
Tragara Pharmaceuticals Appoints Scott Megaffin as Chief Executive Officer and Changes Name to Adastra Pharmaceuticals
Tragara Pharmaceuticals Inc. today announced the appointment of Scott Megaffin as Chief Executive Officer and a member of the Board of Directors effective immediately. Megaffin brings . . .
Posted on 1/3/19
Hackensack Meridian Health and Carrier Clinic Merge
Hackensack Meridian Health, New Jersey's largest and most comprehensive and integrated health network, is proud to announce that Carrier Clinic,
Posted on 1/3/19
Integral Molecular Announces Antibody Discovery Collaboration with Ono Pharmaceutical
Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against multipass membrane proteins, and Ono Pharmaceutical Co., Ltd. today announced that they have . . .
Posted on 1/3/19
Kashiv Pharma Acquires Adello Biologics and Becomes Kashiv BioSciences
Kashiv Pharma, LLC, a pharmaceutical research and drug delivery company developing next-generation technologies, innovative medicines for patients with unmet medical needs
Posted on 1/3/19
Bristol-Myers Squibb To Acquire Celgene
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement
Posted on 1/3/19
Teva and Amgen Resolve Ongoing Dispute Over Teva’s Generic Cinacalet HCl Product
PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced today that it has resolved its ongoing dispute with Amgen over Teva’s generic cinacalcet HCl . . .
Posted on 1/3/19
Alliqua Biomedical CEO Provides Shareholder Update
LANGHORNE, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) --To our Alliqua Shareholders:I hope you have seen our recent exciting announcements that we believe drove the increase in . . .
Posted on 1/3/19
AmerisourceBergen With Cash Flow Secured Trades At 10-Year Low Valuation
SummaryOverwhelmed by negative headlines and headwinds, AmerisourceBergen has tumbled 17% this month compared to a 10% decline for the healthcare sector.At its current share price, shares . . .
Posted on 1/2/19
Hikma Pharmaceutical Plants Sold to Investor Group
Eatontown, New Jersey, Jan. 02, 2019 (GLOBE NEWSWIRE) -- A joint venture between Gordon Brothers and New Mill Capital Holdings has acquired three buildings from Hikma Pharmaceuticals in . . .
Posted on 1/2/19
Intact Vascular Announces Enrollment Completion of TOBA II BTK Clinical Trial
WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced its Tack Optimized Balloon Angioplasty II BTK (TOBA . . .
Posted on 1/2/19
Recro Pharma Amends Athyrium Credit Facility
MALVERN, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute . . .
Posted on 1/1/19
JHU Spinout WindMIL Therapeutics Expands to Philly, Adds Two New Executives
Johns Hopkins spinout WindMIL Therapeutics is opening a new office in Philadelphia as the
Posted on 1/1/19
Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership
MORRIS PLAINS, N.J. and DEVENS, Mass., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) and Johnson Matthey (LSE: JMAT), today announced the companies have . . .
Posted on 12/21/18
Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
MALVERN, Pa., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other . . .
Posted on 12/21/18
Pfizer: Consumer Health Deal Looks Good
Summary Pfizer is combining its consumer business unit in a smart deal with that of GSK. I like the deal which looks smart but is too . . .
Posted on 12/21/18
Johnson & Johnson: Buy The Dip? A 2-Point Analysis
Summary JNJ shares were doing well this year as investors bought Big Pharma, then got hit on a Reuters article. I have reviewed JNJ's product liability . . .
Posted on 12/21/18
Pfizer: Steady As She Goes
Summary If the sell-off continues, we are looking for strong support at the 200 dma. Dividend gets hiked by 6%. We see more mid increases coming. . . .

